Starling Oncology is a community cancer-care operator that spent the summer shedding its old Oncology Institute name just as the business printed its first stretch of positive adjusted earnings. The rename and the Nasdaq ticker change are the visible layer. Underneath, the company is trying to graduate from a California-heavy clinic chain into a multi-state delegated-capitation platform that uses an in-house specialty pharmacy to capture the oral-drug spend sitting next to infusion chairs. That is a harder business than the rebrand implies, because delegated oncology pays a fixed amount per member and then asks the operator to keep medical cost inside the box.
Specialty pharmacy now accounts for most of quarterly revenue, and that mix is why gross profit grew faster than the top line. Patient-services gross profit still declined, because clinical labor was hired ahead of contract launches and because new capitated members arrive expensive. The medical loss ratio on capitated lives moved into the mid-eighties from the low seventies a year earlier, which is the seasonal and onboarding tax that every delegated book pays before pathways bite. First-half operating cash turned positive, yet a large slice of that conversion is accounts payable that rose by $17 million.
Management lifted the full-year revenue range to a $650 million to $670 million band and kept free-cash-flow guidance intact. Adjusted earnings guidance was narrowed rather than raised, which is an honest tell that the company is buying growth with medical-cost noise. The live question is whether Nevada, Oregon, and a delayed Florida statewide delegated book can season inside that thin earnings band, or whether elevated medical cost on new lives keeps the equity priced as a pharmacy story with an option on national capitation.